Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer.

ABSTRACT:

Background

Metastatic colorectal cancer (CRC) continues to be a major health problem, and current treatments are primarily for disease control and palliation of symptoms. In this study, we developed a precision medicine strategy to discover novel therapeutics for patients with CRC.

Methods

Six matched low-passage cell lines and patient-derived xenografts (PDX) were established from CRC patients undergoing resection of their cancer. High-throughput drug screens using a 119 FDA-approved oncology drug library were performed on these cell lines, which were then validated in vivo in matched PDXs. RNA-Seq analysis was then performed to identify predictors of response.

Results

Our study revealed marked differences in response to standard-of-care agents across patients and pi

SUBMITTER: Altunel E 

PROVIDER: S-EPMC7313200 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature